Occidental Petroleum Corporation vs Viatris Inc — how do they compare? Occidental Petroleum Corporation trades at $60.05 (market cap $58.19B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Occidental Petroleum Corporation is far larger — about 2.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.74%). Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and Viatris Inc for 57 Days on average.
| OXY | VTRS | |
|---|---|---|
Market Cap | $58.19B | $20.12B |
Volume | 7,092,290 | 7,543,511 |
Sector | Energy | Health |
52-Week High | $66.24 | $18.27 |
52-Week Low | $38.92 | $9.74 |
Typical Hold Time | 92 Days | 57 Days |
Enterprise Value | $76.95B | $32.24B |
Dividend Yield | 1.92% | 2.74% |
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $58.21, down 0.21% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a 30.32% net income margin and 21.46% ROE, while valuation metrics appear reasonable with a P/E of 17.17 and EV/EBITDA of 5.42. Recent earnings have consistently beaten expectations, and the company maintains a solid balance sheet with $2.13 billion in cash. Analyst consensus is bullish with a $71.40 price target, and the upcoming Q3 2026 earnings report on November 9 is a key catalyst.
OXY presents a compelling investment case with strong fundamentals, reasonable valuation, and positive analyst sentiment. The primary opportunities include continued earnings outperformance, debt reduction progress, and carbon management initiatives. Key risks include oil price volatility, declining revenue trends from $36.6B in 2022 to $21.6B in 2025, and execution challenges in the competitive energy sector. The stock offers upside potential to analyst targets but remains sensitive to commodity price movements.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →